SBIR Phase II: Atlantic Cod Nodavirus Vaccine

这个小企业创新研究（SBIR）二期项目开发了一种重组疫苗，用于预防养殖大西洋鳕鱼的诺达病毒病，大西洋鳕鱼对新英格兰和加拿大大西洋沿岸的渔业日益重要。用于构建疫苗的重组技术是经济、安全的，并产生了一种强有力和有效的产品，可改善鳕鱼的健康。研究涉及重组抗原的合成、配方、安全性、效力和疗效。在转译开发、生产和监管部门批准后，该疫苗将提供给cod生产商，用于预防诺达病毒病。这项研究的更广泛影响将是使新生的鳕鱼养殖业在通过疫苗接种控制病毒疾病的方法方面更容易发展。这符合该国到2020年在不对海洋环境产生负面影响的情况下大幅增加水产养殖产量的愿望。

This Small Business Innovation Research (SBIR) Phase II project of develops a recombinant vaccine for the prevention of nodavirus disease of cultured Atlantic cod, fisheries of growing importanct to New England and Atlantic Canada. The recombinant technology used to build the vaccine is economical, safe and results in a potent and efficacious product that improves cod health. The research addresses recombinant antigen synthesis, formulation, safety, potency and efficacy. After translational development, manufacturing and regulatory approval, the vaccine will be available to cod producers for the prevention of nodavirus disease.The broader impacts of this research will be to enable more facile development of the nascent cod aquaculture industry in respect to methods of viral disease control through vaccination. This is in concert with the desire of the nation to increase aquacultural production significantly by 2020 without impacting the ocean environment negatively.